Tomoverse Imaging, a medical software company specializing in advanced CT imaging for structural heart interventions, has successfully closed a $5 million Seed funding round, led by a Canadian Family Office.
This funding will accelerate the development of Tomoverse’s flagship platform, tvCT. Designed by physicians, tvCT aims to modernize and streamline the planning and execution of complex transcatheter cardiac procedures. The platform offers intuitive, high-performance tools with advanced AI-based automation to enhance accuracy and efficiency in clinical workflows, ultimately improving patient care.
The capital will be used to complete software development, advance clinical studies, and secure regulatory clearances from the U.S. FDA, Health Canada, and other global bodies. Additionally, it will support Tomoverse’s strategic commercialization efforts in North America and key international markets.
Tomoverse’s goal is to become the global standard in CT imaging solutions for the rapidly growing structural heart intervention sector.
KEY QUOTE:
“We are deeply grateful for the trust and confidence placed in us by our investors. This strategic investment accelerates our product roadmap, enabling us to bring our innovative technology closer to patients and clinicians who need it most.”
Stuart Kozlick, CEO of Tomoverse Imaging
